CA9 and renal cell carcinoma: Despite the lack of knowledge about molecular characteristics of G250 antigen, the first clinical trials based on MAb G250 were performed already in 1993 for human renal cell carcinoma treatment, which were soon replaced by clinical studies using chimeric G250 antibody [26].